When was Accipiter Biosciences founded?

Accipiter Biosciences was founded in 2023 and raised its 1st funding round 2 years after it was founded.

Where is Accipiter Biosciences located?

Accipiter Biosciences is headquartered in Seattle, United States.

Who is the current CEO of Accipiter Biosciences?

Matthew J Bick and Bill Arthur s of Accipiter Biosciences. Matthew J Bick has also founded 1 company.

How many employees does Accipiter Biosciences have?

As of Sep 30, 2026, the latest employee count at Accipiter Biosciences is 26.

Is Accipiter Biosciences a funded company?

Accipiter Biosciences is a funded company, having raised a total of $23.2M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 07, 2025.

When was the latest funding round of Accipiter Biosciences?

Accipiter Biosciences' latest funding was a $***** Seed round on Jul 21, 2026, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.68B in funding in 2026 to date.

Where does Accipiter Biosciences rank among its competitors?

Accipiter Biosciences ranks 488th amongst 3783 active competitors, of which 1259 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Accipiter Biosciences, which secured $10.5M in Jul, 2026.

Who are the top competitors of Accipiter Biosciences?

Accipiter Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Accipiter Biosciences secured the most recent funding round in July, 2026.

Accipiter Biosciences - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of de novo protein therapies for complex diseases treatment. These single-agent biologics are custom-engineered to engage multiple pathways. The biologics combine multiple mechanisms in one stable protein molecule. Therapeutic candidates activate more than one cell-surface receptor on the same cell. The platform uses computational methods to create customizable, multifunctional proteins. The company advances a pipeline in autoimmunity and oncology.

Website: accipiterbio.com
Email ID: *****@accipiterbio.com

Key Metrics

Founded Year

2023

Location

Seattle, United States

Stage

Seed

Total Funding

$23.2M in 2 rounds

Latest Funding Round

Seed, Jul 21, 2026, $*****

Investors

Takeda & 7 more

Ranked

488^th among 3783 active competitors

Employee Count

26 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3496 more

View Accipiter Biosciences' full profile

Accipiter Biosciences has raised a total funding of $23.2M over 2 rounds. Its first funding round was on Nov 07, 2025. Accipiter Biosciences has 8 institutional investors.

Here is the list of recent funding rounds of Accipiter Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2026	6909846	Seed	1557106	3729622	5263572	7491051
Nov 07, 2025	4822091	Seed	3273715	8040327	Takeda & 1 more	Columbus Venture Partners & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Accipiter Biosciences's funding rounds and investors

The founders of Accipiter Biosciences are Matthew J Bick, Javier Castellanos, Hector Rincon and Bill Arthur. Bill Arthur and Matthew J Bick are the CEOs of Accipiter Biosciences.

Here are the details of Accipiter Biosciences' key team members:

Matthew J Bick: Co-Founder & CEO of Accipiter Biosciences.
Contact Info: 1 email address
Javier Castellanos: Co-Founder & CTO of Accipiter Biosciences.
Contact Info: 1 email address
Hector Rincon: Co-Founder & CSO of Accipiter Biosciences.
Bill Arthur: Co-Founder & CEO of Accipiter Biosciences.

View details of Accipiter Biosciences's Founder profiles and Board Members

Accipiter Biosciences' employee count trend

Accipiter Biosciences has 26 employees as of Sep 26. Here is Accipiter Biosciences's employee count trend over the years:

Employee count trend for Accipiter Biosciences

Uncover Accipiter Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Accipiter Biosciences include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Accipiter Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
488th	Accipiter Biosciences 2023, Seattle (United States), Seed	Developer of de novo protein therapies for complex diseases treatment	$23.2M	Takeda, Columbus Venture Partners & 6 others	53/100